Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

But sex health assessments are not yet part of oncological clinical practice, despite studies showing that infertility and ...

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...

Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.

The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi (enzalutamide) or Janssen’s Zytiga ...

New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with ...

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to ...

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – ...

Indeed, the global oncology community trusts ESMO to disseminate the latest results of cancer research. Why? Because it is ...

ROCKVILLE, Md. and SUZHOU, China, Sept. 13, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...